CoChat

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML

Björklund, Andreas T., Carlsten, Mattias, Sohlberg, Ebba, Liu, Lisa L., Clancy, Trevor, Karimi, Mohsen, Cooley, Sarah, Miller, Jeffrey S., Klimkowska, Monika, Schaffer, Marie, Watz, Emma, Wikström, Kristina, Blomberg, Pontus, Wahlin, Björn Engelbrekt, Palma, Marzia, Hansson, Lotta, Ljungman, Per, Hellström-Lindberg, Eva, Ljunggren, Hans-Gustaf, Malmberg, Karl-Johan · 2018 · Clinical Cancer Research
Cited by 200

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: To evaluate the safety, efficacy, and immunobiological correlates of allogeneic NK-cell–based therapy in primary chemotherapy-refractory or relapsed high-risk myelodysplastic syndrome (MDS), secondary AML (MDS/AML), and de novo AML patients. Experimental Design: Sixteen patients received fludarabine/cyclophosphamide conditioning combined with total lymphoid irradiation followed by adoptive immunotherapy with IL2–activated haploidentical NK cells. Results: NK-cell infusions were well-tolerated, with only transient adverse events observed in the 16 patients. Six patients achieved objective responses with complete remission (CR), marrow CR, or partial remission (PR). Five patients proceeded to allogeneic hematopoietic stem cell transplantation (HSCT). Three patients are still free from disease >3 years after treatment. All evaluable patients with objective responses (5/5 evaluable) had detectable donor NK cells at days 7/14 following infusion and displayed reduction of tumor cell clones, some of which carried poor prognosis mutations. Residual lin−CD34+CD123+CD45RA+ blast cells in responders had increased total HLA class I and HLA-E expression. Responding patients displayed less pronounced activation of CD8+ T cells and lower levels of inflammatory cytokines following NK-cell infusion. Intriguingly, despite omission of systemic IL2, all patients displayed increased frequencies of activated Ki-67+CD127−FoxP3+CD25hiCD4+ Treg cells of recipient origin following NK-cell therapy. Conclusions: Overall, this study suggests that high-risk MDS is responsive to NK-cell therapy and supports the use of haploidentical NK-cell infusions as a bridge to HSCT in refractory patients. Objective clinical responses and reduction of high-risk clones were associated with detectable donor-derived NK cells, immunoediting of residual blast cells, and less pronounced host immune activation. Clin Cancer Res; 24(8); 1834–44. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-3196

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 200

Metadata

Authors
Björklund, A. T., Carlsten, M., Sohlberg, E., Liu, L. L., Clancy, T., Karimi, M., Cooley, S., Miller, J. S., Klimkowska, M., Schaffer, M., Watz, E., Wikström, K., Blomberg, P., Wahlin, B. E., Palma, M., Hansson, L., Ljungman, P., Hellström-Lindberg, E., Ljunggren, H.-G., & Malmberg, K.-J.
Venue
Clinical Cancer Research
Published
2018-04-12
Volume
24
Issue
8
Pages
1834-1844
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2790461174
Cited by
200
References
9
FWCI
7.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-3196
The paper
Björklund, A. T., Carlsten, M., Sohlberg, E., Liu, L. L., Clancy, T., Karimi, M., Cooley, S., Miller, J. S., Klimkowska, M., Schaffer, M., Watz, E., Wikström, K., Blomberg, P., Wahlin, B. E., Palma, M., Hansson, L., Ljungman, P., Hellström-Lindberg, E., Ljunggren, H.-G., & Malmberg, K.-J. (2018). Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-3196

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.